Target Gene Table
VIS IDVirusEnsembl IDGene TypeTarget GeneOncogeneTumor Suppressor GeneNCBI IDUniprot ID
TVIS30083557HIVENSG00000175868.14protein_codingCALCBNoNo797P10092
TVIS30029105HIVENSG00000175868.14protein_codingCALCBNoNo797P10092
TVIS20001107HPVENSG00000175868.14protein_codingCALCBNoNo797P10092
TVIS20064872HPVENSG00000175868.14protein_codingCALCBNoNo797P10092
TVIS20040972HPVENSG00000175868.14protein_codingCALCBNoNo797P10092
TVIS20049438HPVENSG00000175868.14protein_codingCALCBNoNo797P10092
TVIS20037680HPVENSG00000175868.14protein_codingCALCBNoNo797P10092
TVIS20041789HPVENSG00000175868.14protein_codingCALCBNoNo797P10092
TVIS20067017HPVENSG00000175868.14protein_codingCALCBNoNo797P10092
TVIS20049906HPVENSG00000175868.14protein_codingCALCBNoNo797P10092
TCGA Plot Options
Drug Information
GeneCALCB
DrugBank IDDB14040
Drug NameEptinezumab
Target IDBE0002370
UniProt IDP10092
Regulation Typebinder
PubMed IDs25297013
CitationsDodick DW, Goadsby PJ, Silberstein SD, Lipton RB, Olesen J, Ashina M, Wilks K, Kudrow D, Kroll R, Kohrman B, Bargar R, Hirman J, Smith J: Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: a randomised, double-blind, placebo-controlled, exploratory phase 2 trial. Lancet Neurol. 2014 Nov;13(11):1100-1107. doi: 10.1016/S1474-4422(14)70209-1. Epub 2014 Oct 5.
GroupsApproved; Investigational
Direct ClassificationPeptides
SMILES
Pathways
PharmGKB
ChEMBL